Finch Therapeutics Group, Inc.
FNCH
$13.45
-$0.55-3.93%
| Weiss Ratings | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.64 | |||
| Price History | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.33% | |||
| 30-Day Total Return | 19.03% | |||
| 60-Day Total Return | 12.08% | |||
| 90-Day Total Return | 13.03% | |||
| Year to Date Total Return | 19.03% | |||
| 1-Year Total Return | 425.39% | |||
| 2-Year Total Return | 24.54% | |||
| 3-Year Total Return | -91.09% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -11.67% | |||
| 52-Week Low % Change | 1,650.00% | |||
| Price | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $15.85 | |||
| 52-Week Low Price | $0.80 | |||
| 52-Week Low Price (Date) | May 28, 2024 | |||
| 52-Week High Price (Date) | Feb 20, 2025 | |||
| Valuation | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 22.48M | |||
| Enterprise Value | 35.43M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -8.82 | |||
| Earnings Per Share Growth | -89.68% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.58 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $13.45 | |||
| Enterprise Value/EBITDA (TTM) | -1.82 | |||
| Enterprise Value/EBIT | -1.80 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.61M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 229 6499 | |||
| Address | 75 State Street Boston, MA 02109 | |||
| Website | www.finchtherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -21.89% | |||
| Return on Equity | -- | |||
| Income Statement | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 0.00 | |||
| Total Revenue (TTM) | 0.00 | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 0.00 | |||
| EBITDA (TTM) | -19.51M | |||
| EBIT (TTM) | -19.69M | |||
| Net Income (TTM) | -14.17M | |||
| Net Income Avl. to Common (TTM) | -14.17M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 30.45% | |||
| EPS Diluted (TTM) | -8.82 | |||
| EPS Diluted Growth (Q YOY) | 30.49% | |||
| Balance Sheet | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 16.04M | |||
| Cash Per Share (Q) | $9.99 | |||
| Total Current Assets (Q) | 17.28M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 14.22M | |||
| Current Ratio (Q) | 3.872 | |||
| Book Value Per Share (Q) | $8.86 | |||
| Total Assets (Q) | 45.58M | |||
| Total Current Liabilities (Q) | 4.46M | |||
| Total Debt (Q) | 28.99M | |||
| Total Liabilities (Q) | 31.36M | |||
| Total Common Equity (Q) | 14.22M | |||
| Cash Flow | FNCH - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 71.00K | |||
| Cash from Financing (TTM) | 0.00 | |||
| Net Change in Cash (TTM) | -17.98M | |||
| Levered Free Cash Flow (TTM) | -15.96M | |||
| Cash from Operations (TTM) | -18.06M | |||
